Liver Resection after Disease Control with Abemaciclib for Solitary Liver Metastasis from Breast Cancer: A Case Report
Open accessThe DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index; 12 of the 21 sources its claims cite were checked for support.
Abstract
INTRODUCTION: Liver metastases from breast cancer are associated with a poorer prognosis than bone or soft tissue metastases. In hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative recurrent or metastatic breast cancer, endocrine therapy combined with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors has been established as the standard of care. Abemaciclib has demonstrated favorable efficacy in phase III clinical trials and is considered an important option for long-term disease control. With recent advances in systemic therapy, an increasing number of patients achieve sustained disease control; however, prolonged treatment may lead to impaired QOL, financial burden, and the need for long-term therapy. Consequently, the role of local treatment in carefully selected patients with well-controlled disease has increasingly been discussed. Here, we report a case of breast cancer with postoperative recurrent solitary liver metastasis in which disease control was achieved with endocrine therapy plus abemaciclib, followed by liver resection, resulting in long-term recurrence-free survival. CASE PRESENTATION: A 45-year-old woman with HR-positive, HER2-negative breast cancer underwent breast-conserving surgery followed by adjuvant chemotherapy, radiotherapy, and endocrine therapy. Five years after surgery, follow-up CT revealed a solitary liver lesion. Percutaneous biopsy demonstrated adenocarcinoma consistent with a solitary liver metastasis from breast cancer. Combination therapy with a luteinizing hormone-releasing hormone agonist, fulvestrant, and abemaciclib was initiated. Although dose reduction of abemaciclib was required because of grade 3 neutropenia, stable disease was maintained for approximately 1 year. Given the sustained disease control, absence of extrahepatic metastasis, and the patient's strong preference, laparoscopic liver resection was performed after obtaining informed consent. Pathological examination revealed adenocarcinoma consistent with metastatic breast cancer, with negative surgical margins. Postoperatively, endocrine therapy alone was continued, and the patient has remained recurrence-free for 3 years after liver resection. CONCLUSIONS: This case represents a rare report of surgical resection for breast cancer liver metastasis after CDK4/6 inhibitor-based therapy. It suggests that local treatment may be effective even in cases with suspected endocrine-resistant disease and provides practical insight into patient selection and treatment strategies, as the case fulfilled previously reported criteria for local therapy.
Overview
CoChat Summary
## TL;DR
This case report describes a 45-year-old woman with HR-positive, HER2-negative breast cancer who developed a solitary liver metastasis, achieved about 1 year of stable disease on fulvestrant plus abemaciclib, and then underwent laparoscopic liver resection. She remained recurrence-free for 3 years after surgery, suggesting local treatment may be an option in carefully selected patients with well-controlled disease.
## Key findings
- A solitary liver lesion measuring 28.5 mm was found 5 years after breast-conserving surgery; biopsy confirmed metastatic breast cancer.
- With luteinizing hormone–releasing hormone agonist + fulvestrant + abemaciclib, the liver lesion remained stable for approximately 1 year by RECIST 1.1, despite grade 3 neutropenia requiring abemaciclib dose reduction from 300 to 100 mg/day.
- After laparoscopic posterior sectionectomy with cholecystectomy, pathology showed metastatic adenocarcinoma with negative margins and the patient has remained recurrence-free for 3 years after liver resection.
- The authors note that in phase III trials of abemaciclib, median progression-free survival was 29.0 months and median overall survival was 66.8 months when used first-line, and they compare the patient’s recurrence-free interval of 4 years from abemaciclib initiation with these trial outcomes.
## Methods
- Design: Single-patient case report.
- Data/sample: One 45-year-old woman with HR-positive, HER2-negative breast cancer and a solitary liver metastasis.
- Main analysis: Clinical course tracked with CT, FDG-PET/CT, biopsy, immunohistochemistry, tumor markers, and response assessment using RECIST 1.1; pathology after resection confirmed metastatic breast cancer and margin status.
## Limitations
- The paper is a single case report, so the text itself only supports an anecdotal conclusion and does not establish general effectiveness.
- The authors state that evidence for liver resection in this setting comes from non-randomized retrospective studies and is subject to selection bias and heterogeneity.
- The report does not provide comparative data against non-surgical management in similar patients; this is evident from the text.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
9 Valid · 0 Not valid · 6 Not checked · 13 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“In patients with HR–positive and HER2–negative recurrent or metastatic breast cancer, endocrine therapy combined with CDK4/6 inhibitors has been established as the current standard of care.2)”
§ Liver Resection after Disease Control with Abemaciclib for Solitary Liver Metastasis from Breast Cancer: A Case Report > INTRODUCTION
What the sources say
- Supportedcites [2] 2) Cardoso F, Paluch-Shimon S, Senkus E, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol 2020; 31: 1623–49. source
In the discussion of ER-positive/HER2-negative advanced breast cancer (page unavailable in our copy), the ABC 5 panel recommends a CDK4/6 inhibitor plus endocrine therapy as first-line treatment where the drugs are available. It also acknowledges that a small group of patients may receive endocrine therapy alone, which does not undermine the claim about the general standard of care. (LLM, conf=0.88)
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“recent retrospective studies have suggested that liver resection may be associated with prolonged survival in selected patients, defined as those with a solitary or limited number of liver metastases, good disease control under systemic therapy, no evidence of uncontrolled extrahepatic disease, technically feasible R0 resection, and adequate performance status to tolerate surgery.8–11)”
§ Liver Resection after Disease Control with Abemaciclib for Solitary Liver Metastasis from Breast Cancer: A Case Report > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites [8] 8) Yoo TG, Cranshaw I, Broom R, et al. Systematic review of early and long-term outcome of liver resection for metastatic breast cancer: Is there a survival benefit? Breast 2017; 32: 162–72. source
- Partly supportedcites [9] 9) Sundén M, Hermansson C, Taflin H, et al. Surgical treatment of breast cancer liver metastases - A nationwide registry-based case control study. Eur J Surg Oncol 2020; 46: 1006–12. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Not checked — no full text of the sourcecites [10] 10) Ruiz A, van Hillegersberg R, Siesling S, et al. Surgical resection versus systemic therapy for breast cancer liver metastases: Results of a European case matched comparison. Eur J Cancer 2018; 95: 1–10. source
- Partly supportedcites [11] 11) Chun YS, Mizuno T, Cloyd JM, et al. Hepatic resection for breast cancer liver metastases: Impact of intrinsic subtypes. Eur J Surg Oncol 2020; 46: 1588–95. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“when complete resection is feasible, surgical resection may provide more favorable long-term outcomes.18)”
§ Liver Resection after Disease Control with Abemaciclib for Solitary Liver Metastasis from Breast Cancer: A Case Report > DISCUSSION
What the sources say
- Partly supportedcites [18] 18) Rangarajan K, Lazzereschi L, Votano D, et al. Breast cancer liver metastases: systematic review and time to event meta-analysis with comparison between available treatments. Ann R Coll Surg Engl 2023; 105: 293–305. sourceExperimental — accuracy not yet measured
The Survival outcome section (page not provided) reports higher five-year survival in the surgical group than in the ablation group, supporting the possibility of more favorable long-term outcomes. The paper does not establish that advantage specifically when complete resection is feasible; its Conclusions (page not provided) say the data are insufficient to directly compare the treatments or define patient-selection strategies. (LLM, conf=0.85)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the liver lesion remained controlled for approximately 1 year, with stable disease confirmed according to the RECIST version 1.1”
§ Liver Resection after Disease Control with Abemaciclib for Solitary Liver Metastasis from Breast Cancer: A Case Report > CASE PRESENTATION
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Postoperatively, disease control was maintained with endocrine therapy alone”
§ Liver Resection after Disease Control with Abemaciclib for Solitary Liver Metastasis from Breast Cancer: A Case Report > DISCUSSION
plainstates a causeSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
7 more claims
Create a free account to see all 28 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 13
- Probably not a substantial claim. 5
Citations
Cites
Clonal heterogeneity and tumor evolution: past, present, and the future
McGranahan, N., & Swanton, C. (2017) · Cell · doi:10.1016/j.cell.2017.01.018 · Cited by 2,840
Hellman, S., & Weichselbaum, R. R. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.1.8 · Cited by 2,562
Giuliano, A. E., Ballman, K. V., McCall, L., Beitsch, P. D., Brennan, M. B., Kelemen, P. R., Ollila, D. W., Hansen, N. M., Whitworth, P. W., Blumencranz, P. W., et al. (2017) · JAMA · doi:10.1001/jama.2017.11470 · Cited by 1,912 · cited 1×
“21) Although PgR expression was decreased in the liver metastasis, HR and HER2 status are known to change between primary and metastatic lesions, 22) and cytokeratin 7 positivity further supported the diagnosis of metastatic breast cancer.”
Sledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.7585 · Cited by 1,680 · cited 1×
“23) The patient had a solitary liver metastasis from HR-positive/HER2-negative breast cancer that remained stable for approximately 1 year under endocrine therapy combined with abemaciclib.”
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M. S., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G. S., Biganzoli, L., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.09.010 · Cited by 1,369
Image-guided Tumor Ablation: Standardization of Terminology and Reporting Criteria—A 10-Year Update
Ahmed, M., Solbiati, L., Brace, C. L., Breen, D. J., Callstrom, M. R., Charboneau, J. W., Chen, M.-H., Choi, B. I., de Baère, T., Dodd, G. D., et al. (2014) · Radiology · doi:10.1148/radiol.14132958 · Cited by 1,346
Amir, E., Miller, N., Geddie, W., Freedman, O., Kassam, F., Simmons, C., Oldfield, M., Dranitsaris, G., Tomlinson, G., Laupacis, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5232 · Cited by 434 · cited 1×
“21) Although PgR expression was decreased in the liver metastasis, HR and HER2 status are known to change between primary and metastatic lesions, 22) and cytokeratin 7 positivity further supported the diagnosis of metastatic breast cancer.”
Beaver, J. A., Amiri-Kordestani, L., Charlab, R., Chen, W., Palmby, T., Tilley, A., Zirkelbach, J. F., Yu, J., Liu, Q., Zhao, L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1185 · Cited by 373
Goetz, M. P., Toi, M., Huober, J., Sohn, J., Trédan, O., Park, I. H., Campone, M., Chen, S.-C., Manso, L. M., Paluch-Shimon, S., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.04.013 · Cited by 238
Ehsan, A. N., Wu, C. A., Minasian, A., Singh, T., Bass, M., Pace, L., Ibbotson, G. C., Bempong-Ahun, N., Pusic, A., Scott, J. W., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.55388 · Cited by 183
Ahmed, M. (2014) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2014.09.005 · Cited by 180
Atalay, G., Biganzoli, L., Renard, F., Paridaens, R., Čufer, T., Coleman, R. E., Calvert, H., Gamucci, T., Minisini, A. M., Therasse, P., et al. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00601-4 · Cited by 111 · cited 1×
“12) Subtype-specific analyses have shown that patients with HR-positive/HER2-negative breast cancer and liver metastases have the second poorest prognosis after those with triple-negative disease, with reported median progression-free survival of approximately 7–8 months and overall survival of…”
Ruiz, A., van Hillegersberg, R., Siesling, S., Castro-Benitez, C., Sebagh, M., Wicherts, D. A., de Ligt, K. M., Goense, L., Giacchetti, S., Castaing, D., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.02.024 · Cited by 84
Yoo, T. G., Cranshaw, I., Broom, R., Pandanaboyana, S., & Bartlett, A. (2017) · The Breast · doi:10.1016/j.breast.2017.02.003 · Cited by 44
Effects of Yttrium-90 selective internal radiation therapy on non-conventional liver tumors
Kuei, A. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i27.8271 · Cited by 38 · cited 2×
“1) In most cases, liver metastases occur during disease progression and are frequently diagnosed as diffuse or multiple lesions and/or with concomitant metastases to other organs.”
Hepatic resection for breast cancer liver metastases: Impact of intrinsic subtypes
Chun, Y. S., Mizuno, T., Cloyd, J. M., Ha, M. J., Omichi, K., Tzeng, C.-W. D., Aloia, T. A., Ueno, N. T., Kuerer, H. M., Barcenas, C. H., et al. (2020) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2020.03.214 · Cited by 32 · cited 1×
“11 patient selection and treatment strategies, as the case fulfilled previously reported criteria for local therapy.”
Sundén, M., Hermansson, C., Taflin, H., Andersson, A., Sund, M., & Hemmingsson, O. (2020) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2020.02.008 · Cited by 28
Prognosis and Genomic Landscape of Liver Metastasis in Patients With Breast Cancer
Tian, C., Liu, S., Wang, Y., & Song, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.588136 · Cited by 25
Rangarajan, K., Lazzereschi, L., Votano, D., & Hamady, Z. (2023) · The Annals of The Royal College of Surgeons of England · doi:10.1308/rcsann.2021.0308 · Cited by 16 · cited 1×
“18) In this case, if RFA had been selected, the tumor location adjacent to the right hepatic vein may have reduced the efficacy of thermal ablation due to the heat sink effect, 19) and tumors near major vessels are associated with higher local recurrence rates.”
Receptor conversion and survival in breast cancer liver metastases
Sundén, M., Norgren, S., Lundqvist, R., Andersson, A., Sund, M., & Hemmingsson, O. (2023) · Breast Cancer Research · doi:10.1186/s13058-023-01706-4 · Cited by 14
Factors Affecting Health-Related Quality of Life in Patients With Metastatic Breast Cancer
Park, M., Yu, S.-Y., Jeon, H.-L., & Song, I. (2023) · Journal of Breast Cancer · doi:10.4048/jbc.2023.26.e29 · Cited by 13
Radiofrequency Ablation of Hepatic Metastases: Factors Influencing Local Tumor Progression
Liu, C.-H., Yu, C.-Y., Chang, W.-C., Dai, M.-S., Hsiao, C.-W., & Chou, Y.-C. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3738-y · Cited by 10
Fertility preservation in breast cancer patients
Shien, T., Nakatsuka, M., & Doihara, H. (2014) · Breast Cancer · doi:10.1007/s12282-013-0463-5 · Cited by 7
17) ClinicalTrialsgov. BRECLIM: Breast Cancer Liver Metastases. Identifier: NCT04079049. Available from:https://clinicaltrials.gov/ct2/show/NCT04079049. Accessed February 24, 2026.
(n.d.)
Unresolved
Metadata
- Authors
- Kurokawa, Y., Terakawa, H., Mohri, R., Hirata, M., Gabata, R., Yagi, S., & Inaki, N.
- Affiliations
- Kanazawa University Hospital (JP)
- Corresponding author
- Kurokawa, Yuki
- ORCID
- Venue
- Surgical case reports
- Publisher
- Japan Surgical Society
- Published
- 2026
- Volume
- 12
- Issue
- 1
- Pages
- n/a
- ISSN
- 2198-7793 (ISSN-L)
- PMC
- PMC13242950
- OpenAlex
- W7163542200
- Cited by
- 0
- References
- 23
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Surgical Case Reports (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Metastasis and carcinoma case studies
- Keywords
- breast cancer, liver metastasis, abemaciclib, CDK4/6 inhibitors, endocrine therapy, fulvestrant, laparoscopic liver resection, hormone receptor-positive HER2-negative breast cancer, recurrence-free survival, neutropenia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.